A7986

Atovaquon

≥98% (HPLC), powder, anti-protozoal agent

• Synonym(e): 2-[trans-4-(4-Chlorphenyl)cyclohexyl]-3-hydroxy-1,4-naphthochinon, Mepron
• Empirische Formel (Hill-System): C₂₂H₁₉ClO₃
• CAS-Nummer: 95233-18-4
• Molekulargewicht: 366.84
• MDL number: MFCD00889188
• UNSPSC Code: 12352200
• PubChem Substance ID: 329770944
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: Atovaquon, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: yellow
• solubility: DMSO: >10 mg/mL
• originator: GlaxoSmithKline
• storage temp.: −20°C
• SMILES string: OC1=C([C@H]2CC[C@@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O
• InChI: 1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-
• InChI key: KUCQYCKVKVOKAY-CTYIDZIISA-N

Beschreibung

Application

Atovaquone inhibits the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket. In addition to its use as a treatment for toxoplasmosis, atovaquone has antimalarial properties and prevents pneumocystis pneumonia post-renal transplant.

Biochem/physiol Actions

Atovaquone in an anti-protozoal mitochondrial electron transport inhibitor. It also functions as an antimalarial and antipneumocystic agent.

Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It is an analog of protozoan mitochondrial protein ubiquinone, and acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable